Comparisons according to statin use
| No statins (n=192) | On statins (n=154) | p Value | |
|---|---|---|---|
| Demographic data | |||
| Age (years) | 52 (42–58) | 55 (48–61) | <0.001 |
| Male sex (n (%)) | 65 (34) | 73 (47) | 0.011 |
| Bariatric cohort (n (%)) | 114 (59) | 94 (61) | 0.753 |
| Metabolic data | |||
| BMI (kg/m2) | 42 (32–50) | 42 (33–49) | 0.873 |
| High blood pressure (n (%)) | 123 (64) | 138 (90) | <0.001 |
| On antidiabetic drugs (n (%)) | 150 (78) | 142 (92) | <0.001 |
| Number of antidiabetic drugs | 1 (1–2) | 2 (1–2.25) | <0.001 |
| Metformin (n (%)) | 125 (65) | 131 (85) | <0.001 |
| Sulfonylureas (n (%)) | 48 (25) | 65 (42) | 0.001 |
| Insulin (n (%)) | 33 (17) | 51 (33) | 0.001 |
| Metabolic syndrome (n (%)) | 160 (88) | 152 (100) | <0.001 |
| Biochemical data | |||
| HbA1c (%) | 7.0 (6.3–7.7) | 7.5 (6.7–8.5) | <0.001 |
| Triglyceridaemia (mmol/L) | 1.7 (1.2–2.7) | 1.7 (1.1–2.4) | 0.567 |
| Total cholesterol (mmol/L) | 5.0 (4.3–5.7) | 4.3 (3.8–5.1) | <0.001 |
| HDL cholesterol (mmol/L) | 1.1 (0.9–1.4) | 1.1 (1.0–1.3) | 0.518 |
| AST (U/L) | 32 (25–46) | 31 (23–43) | 0.178 |
| ALT (U/L) | 42 (29–64) | 39 (25–61) | 0.218 |
| GGT (U/L) | 50 (31–86) | 54 (33–92) | 0.286 |
| Histological data | |||
| NASH (n (%)) | 108 (56) | 88 (57) | 0.868 |
| Significant fibrosis (F≥2) (n (%)) | 93 (48) | 74 (48) | 0.943 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; GGT, γ glutamyl transpeptidase; HbA1c, glycated haemoglobin.